 Home > Active Ingredient News > Drugs Articles > Semi-annual report of Tianjing Bio: will submit a CD38 antibody listing application and start the research and development of "super antibody"

Semi-annual report of Tianjing Bio: will submit a CD38 antibody listing application and start the research and development of "super antibody"

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

ph products

cultivation innovation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 31, Tianjing Bio-Bio announced the first half of 2021 results and the company's current status
.
According to the report, the core research and development expenditure of Tianjing Bio-Bio was RMB 480 million in the first half of the year

It is expected to submit a new drug listing application for the CD38 antibody fezetuzumab (TJ202) to the National Medical Products Administration (NMPA) in the fourth quarter of this year.

Progress in monoclonal antibody product pipeline

TJ202 is a differentiated CD38 antibody , which is expected to treat multiple myeloma and systemic lupus erythematosus
.
The drug is the first product in the existing R&D pipeline of Tianjing Bio to reach the end of the registered clinical trial .

It is suitable for the third-line treatment of multiple myeloma.

TJ202 is a differentiated CD38 antibody.

TJ101 (Itan Growth Hormone Alpha) is a differentiated long-acting recombinant human growth hormone

TJC4 (lemzoparlimab) is a differentiated CD47 antibody .
TJC4 has reached a global strategic cooperation with AbbVie on this drug
.
Currently, Tianjing Biological is advancing a number of clinical studies of TJC4 at the same time in China and the United States

TJC4 (lemzoparlimab) is a differentiated CD47 antibody for hematological tumor indications for solid tumor indications

TJD5 (uliledlimab) is a differentiated CD73 antibody
.
In May 2021, TJBio announced the results of the Phase 1 clinical study of TJD5 combined with atelizumab in the treatment of patients with advanced cancer at the annual meeting of the American Society of Clinical Oncology (ASCO), and was selected as the 2021 ASCO annual meeting "Top 12" research abstract

TJD5 (uliledlimab) is a differentiated CD73 antibody

In addition to the above-mentioned products, Tianjing Bio’s monoclonal antibody product pipeline has a number of drugs under research that have ushered in research progress, including: TJM2 (plonmarlimab), a GM-CSF monoclonal antibody; TJ107 (effective interleukin α), one Long-acting human recombinant interleukin-7; TJ301 (Oxicept), a differentiated interleukin-6 signaling pathway inhibitor; TJ271 (Ebutuximab), a highly differentiated B7-H3 monoclonal antibody ; TJ210.
A highly differentiated antibody that can target myeloid-derived suppressor cells in tumors and autoimmune diseases
.

Image source: 123RF

Progress of bispecific antibodies and "super antibodies"

In an interview with WuXi AppTec's content team, Dr.
Jingwu Zang, the founder and chairman of Tianjing Bio, said that "innovation" has always been one of the core strengths of Tianjing Bio
.
Since its establishment, Tianjing Bio has experienced two rounds of innovation iterations

In the first half of 2021, the various bispecific antibody pipelines of Tianjing Biologics also ushered in many developments
.
TJ-CD4B is a bispecific antibody targeting Claudin 18.

2 and 4-1BB jointly developed by Tianjing Bio and ABL Bio

TJ-CD4B, a bispecific antibody targeting Claudin 18.

TJ-L14B, by blocking PD-L1 signal and stimulating 4-1BB signal, activates T cells to produce anti-tumor synergistic effects

In the field of "super antibody" research and development, Tianjing Bio is actively looking for platforms and companies with cutting-edge technology as partners to build a new generation of tumor immune innovation pipeline through their unique revolutionary technology
.
Up to now, Tianjing Bio has reached four cooperations with Complix, Affinity, Jiachen Xihai, and Xingkangyuan Bio, and obtained the cell penetrating antibody (CPAB) technology platform and tumor local antibody activation.

Covert antibody technology, self-replicating mRNA technology, artificial intelligence (AI) technology
.

To build a new generation of tumor immune innovation pipeline through their unique revolutionary technology

Tianjing Biotech stated in a press release that the company expects to complete the transformation from a research and development biotechnology company to a comprehensive global biopharmaceutical company in the next 3-4 years
.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.

Reference materials:

[1] Tianjing Biotech announced the first half of 2021 results and the company's current status.
Retrieved Sep 1.
2021.
from https://mp.
weixin.
qq.
com/s/hXmFF8L3_nwxJj9yAbutSg

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.